+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Open-Angle Glaucoma- Market Insight, Epidemiology and Market Forecast -2030

  • ID: 4855538
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 150 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Aerie Pharmaceuticals
  • Allergan
  • Bausch and Lomb
  • Envisia Therapeutics
  • Merck Sharp & Dohme Corp.
  • Nicox Ophthalmics
  • MORE
Open-angle glaucoma (OAG) - Market Insights, Epidemiology, and Market Forecast - 2030 (7MM) report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous humor through the trabecular meshwork of the eye's anterior chamber. The current treatment management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. However, these treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. Besides these pharmacological treatment measurements, incisional surgery, laser surgery, and medication are also preferred.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Open-angle glaucoma - Disease Understanding and Treatment Algorithm

Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous humor through the trabecular meshwork of the eye's anterior chamber. It is the most common form of glaucoma which accounts for the majority of the glaucoma cases.

OAG is primarily divided into two subtypes, i.e., Primary OAG and Secondary OAG. The risk factors of OAG are divided into four categories, general factors, ocular factors, nonocular factors, and ocular hypertension.

Open-angle glaucoma - Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Glaucoma in the 7MM, Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM, Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM, Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM and Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM scenario of OAG in the 7MM countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

As per the analysis, a higher percentage of diagnosed prevalence of OAG was observed for females, in comparison to males, in all the 7MM countries. The research analysts have assessed that the total prevalent population of Glaucoma in the 7MM was 9,819,080 in 2017. In addition to this, it was also assessed that among those with glaucoma in the 7MM, more than 8.5 million were diagnosed with OAG.

Open-angle glaucoma - Drug Chapters

This segment of the Open-angle glaucoma (OAG) report encloses the detailed analysis of marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The treatment and market of OAG are dependent on the class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. In emerging therapies following drugs are there Bimatoprost SR (Allergan), PDP - 716 (Sun Pharma), Trabodenoson (Inotek Pharmaceuticals), DE-30A (Santen), and others.

Prostaglandin derivatives, beta-blockers, Topical carbonic anhydrase inhibitors (CAIs), alpha2-adrenergic receptor agonists and Combination therapies are the most preferred classes for the treatment of open-angle glaucoma. In the United States, drugs of this class have been approved in the past few years like Vyzulta, Xelpros, Travatan Z, and a few others by the US FDA. Rhopressa which is marketed in both the US and Europe (Rhokiinsa), has recently completed the phase II trial in Japan. The company is looking to meet with Japan's Pharmaceutical and Medical Devices Agency to discuss these results and identify the next steps for a phase III program in Japan. Apart from this, Ube Industries and Santen Pharmaceutical in Japan developed a famous ophthalmic product known as Omidenepag isopropyl ophthalmic solution 0.002 %, which is marketed under the name of EYBELIS is a selective prostaglandin E2 receptor 2 agonist with a non-prostaglandin structure for the treatment of glaucoma and ocular hypertension.

There are several unmet needs in the management of Glaucoma and to meet these unmet needs, various pharmaceutical companies have started working toward the development of the novel product for this indication. Pharmaceutical companies, like Allergan, Sun Pharma Advanced Research Company (SPARC) Limited, Laboratorios Sophia S.A de C.V., Nicox Ophthalmics, and Nicox Ophthalmics developing products that have the potential to change the open-angle glaucoma treatment landscape.

Allergan's drug candidate, Bimatoprost SR is a biodegradable sustained-release implant, which is currently under development in phase III for the treatment of OAG and ocular hypertension. The solid, rod-shaped implant consists of the prostaglandin analog (PGA) bimatoprost within the company's Novadur platform for drug delivery. In July 2019, the United States Food and Drug Administration (US FDA) accepted Allergan's new drug application for bimatoprost sustained-release in patients with OAG or ocular hypertension. The FDA is expected to take action on the NDA by the end of the first half of 2020.

PDP - 716 is the once-a-day formulation of Brimonidine developed using SPARC's TearActTM Technology for treatment of Glaucoma by Sun Pharma. PDP - 716 provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. SPARC initiated the pivotal Phase III study for PDP - 716 in the USA. The study is randomizing patients and is expected to be completed by Q4 FY 2020. SPARC is in discussion with potential partners for licensing of PDP - 716.

Among all these mentioned companies Santen is constantly working to meet the unmet needs of the OAG. Two of its products are in pipeline (phase II and Phase III), i.e., DE-130A and Sepetaprost (ONO-9054). DE-130A is an ophthalmic emulsion of a prostaglandin F2α derivative, for the treatment of glaucoma and ocular hypertension. This product is in phase III clinical development stage. Santen recently initiated the phase III trial in Europe and Asia and planning to complete it in 2021. On the other hand, ONO-9054 is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). ONO-9054 is expected to show a superior intraocular pressure (IOP) lowering effect compared to FP receptor agonists.

The company has completed the Phase II clinical trial of ONO-9054 for the treatment of glaucoma and ocular hypertension in the US. In the future, Santen will seek manufacturing and marketing approval for ONO-9054 on a worldwide basis. There are several other products in the clinical development for the treatment of OAG.

Open-angle glaucoma - Market Outlook

The Open-angle glaucoma (OAG) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trends of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

As per the assessment, it has been observed that the market size of OAG was observed to be USD 3,316.71 million in 2017, in the 7MM. Among all the seven major markets, the United States covers the major market share that accounts for 41.01% of the 7MM. In 2017, the market size was accessed to be USD 1,360.30 million in the country.

The products which are anticipated to be launched in the 7MM include Bimatoprost SR (Sustained-Release; Allergan), DE-117 (omidenepag isopropyl; Santen Pharmaceutical); PRO-122 (Laboratorios Sophia); PDP - 716 (Brimonidine; Sun Pharma); Sepetaprost (DE-126/ONO-9054: Santen/Ono Pharmaceutical); NCX 470 (Nicox Ophthalmics) and Nyxol (Phentolamine Mesylate: Ocuphire Pharma). However, in addition to this, it is anticipated that Aerie Pharma with its two products ROCKLATAN and RHOPRESSA/Rhokiinsa will definitely show an impact on the open-angle glaucoma market of Europe. Recently, in November 2019, the European Commission (EC) granted marketing authorization to Rhokiinsa 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.

Besides this Sun Pharma Advanced Research Company (SPARC) is also expecting the launch of its product PDP - 716 (Brimonidine). In addition to this, a product named), DE-130A (of Santen Pharmaceutical is also anticipated to be launched in the European countries. ROCKLATAN and RHOPRESSA are approved in the US and recently Aerie pharma received a positive opinion from the CHMP. This positive opinion will help in the smooth launch of RHOPRESSA (under the name RHOKIINSA).

Some of these products have completed the late clinical stages of development, while others are in ongoing late clinical development stages. These drug candidates have shown very promising results and it has been anticipated by the research analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of OAG will have better management practices.

Open-angle glaucoma (OAG) - Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

The current therapeutic landscape of advanced stage OAG in the 7MM is driven by several approved therapies, including those with generic products. Of this, majority of the market share is accommodated by Prostaglandin analogs generating USD 1,806.12 million, followed by Carbonic anhydrase inhibitors generating USD 578.42 million while Miotics contributed the least towards the market share, with USD 146.31 million.

To meet the unmet need of the market and to provide better versions of current treatment practices, several companies have shifted their focus toward this therapeutic area, and several therapies are expected to enter the treatment market of OAG during our forecast period, including In emerging therapies following drugs are there Bimatoprost SR (Allergan), PDP - 716 (Sun Pharma.), DE-130A (Santen), and others.

Open-angle glaucoma Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Open-angle glaucoma Report Key Strengths
  • 11 Years Forecast
  • 7MM Countries Coverage
- Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake
Open-angle glaucoma Report Assessment
  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Open-angle glaucoma market
  • Organize sales and marketing efforts by identifying the best opportunities for Open-angle glaucoma market
  • To understand the future market competition in the Open-angle glaucoma market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aerie Pharmaceuticals
  • Allergan
  • Bausch and Lomb
  • Envisia Therapeutics
  • Merck Sharp & Dohme Corp.
  • Nicox Ophthalmics
  • MORE
1. Key Insights

2. Executive Summary of Open-Angle Glaucoma

3. Open-Angle Glaucoma (OAG): Market Overview at a Glance
3.1. Total Market Share (%) Distribution of OAG in 2017
3.2. Total Market Share (%) Distribution of OAG in 2030

4. Open-Angle Glaucoma: Disease Background and Overview
4.1. Introduction
4.2. Classification of Open-Angle Glaucoma
4.3. Signs and Symptoms of Open-Angle Glaucoma
4.4. Risk Factors of Primary Open-Angle Glaucoma (POAG)
4.4.1. General
4.4.2. Ocular
4.4.3. Nonocular
4.4.4. Ocular Hypertension
4.5. Pathophysiology of Primary Open-Angle Glaucoma (POAG)
4.6. Genes Involved in Primary Open-Angle Glaucoma
4.6.1. Myocilin
4.6.2. Optineurin
4.6.3. TANK-binding Kinase-1 (TBK1)
4.6.4. WD-repeat domain 36 (WDR36, OMIM 609669)
4.7. Biomarkers associated with Primary Open Angle Glaucoma (POAG)
4.8. Diagnosis of Open-Angle Glaucoma
4.8.1. Diagnosis of Primary Open-Angle Glaucoma
4.8.2. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines

5. Case Reports
5.1. Managing Juvenile Open-Angle Glaucoma
5.2. Visual improvement following glaucoma surgery: a case report
5.3. Evidence-based medicine in glaucoma surgery

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology and Market Methodology
6.3. Total Prevalence of Glaucoma in the 7MM
6.4. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM
6.5. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalence of Glaucoma in the United States
7.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United States
7.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
7.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
7.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States

8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Prevalence of Glaucoma in Germany
8.1.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany
8.1.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
8.1.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
8.1.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
8.2. France Epidemiology
8.2.1. Assumptions and rationale
8.2.2. Total Prevalence of Glaucoma in France
8.2.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France
8.2.4. Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
8.2.5. Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
8.2.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Total Prevalence of Glaucoma in Italy
8.3.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy
8.3.4. Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
8.3.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
8.3.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Prevalence of Glaucoma in Spain
8.4.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain
8.4.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
8.4.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
8.4.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Total Prevalence of Glaucoma in the United Kingdom
8.5.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom
8.5.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
8.5.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
8.5.6. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Total Prevalence of Glaucoma in Japan
9.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan
9.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
9.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
9.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

10. Treatment Algorithm, Current Treatment, and Medical Practices
10.1. Treatment Algorithm for Open-Angle Glaucoma
10.2. Treatment and Management for Open-Angle Glaucoma
10.2.1. Basis for Treatment
10.2.2. Available Treatment Options
10.2.3. Medical (Pharmaceutical) Treatment
10.2.4. Laser Trabeculoplasty
10.2.5. Surgery
10.3. Treatment Guidelines
10.3.1. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines
10.3.2. European Glaucoma Society Terminology and Guidelines for Glaucoma
10.4. Prognosis and Follow-up of Open-Angle Glaucoma
10.4.1. Prognosis
10.4.2. Frequency of Follow-up
10.4.3. Therapy Modification
10.4.4. Effectiveness of Treatment
10.5. Management of Patients with Severe, Irreversible Vision Loss

11. Unmet Needs

12. Marketed Products
12.1. Marketed Products And Their Relative Therapeutic Classes
12.2. Rocklatan: Aerie Pharmaceuticals
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Clinical Development
12.2.4. Safety and efficacy
12.2.5. Adverse Reaction
12.2.6. Product Profile
12.3. Rhopressa: Aerie Pharmaceuticals
12.3.1. Product Description
12.3.2. Regulatory Milestones
12.3.3. Clinical Development
12.3.4. Safety and efficacy
12.3.5. Product Profile
12.4. XELPROS (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited
12.4.1. Product Description
12.4.2. Regulatory Milestones
12.4.3. Clinical Development
12.4.4. Product Profile
12.5. EYBELIS Ophthalmic Solution 0.002% (DE-117, Omidenepag isopropyl): Santen Pharmaceutical/Ube Industries
12.5.1. Product Description
12.5.2. Regulatory Milestones
12.5.3. Clinical Development
12.5.4. Safety and efficacy
12.5.5. Product Profile
12.6. VYZULTA: Bausch and Lomb
12.6.1. Product Description
12.6.2. Regulatory Milestones
12.6.3. Clinical Development
12.6.4. Safety and efficacy
12.6.5. Product Profile
12.7. TAPCOM/ DE-111 (Tafluprost/timolol maleate): Santen Pharmaceutical Co., Ltd.
12.7.1. Product Description
12.7.2. Regulatory Milestones
12.7.3. Clinical Development
12.7.4. Product Profile
12.8. GLANATEC: D.Western Therapeutics Institute (DWTI)/Kowa LTD.
12.8.1. Product Description
12.8.2. Regulatory Milestones
12.8.3. Clinical Development
12.8.4. Safety and Efficacy
12.8.5. Product Profile
12.9. Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon Research
12.9.1. Product Description
12.9.2. Regulatory Milestones
12.9.3. Clinical Development
12.9.4. Safety and efficacy
12.9.5. Product Profile
12.10. ZIOPTAN (tafluprost): Merck Sharp & Dohme Corp.
12.10.1. Product Description
12.10.2. Regulatory Milestones
12.10.3. Clinical Development
12.10.4. Safety and efficacy
12.10.5. Product Profile
12.11. DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research
12.11.1. Product Description
12.11.2. Regulatory Milestones
12.11.3. Clinical Development
12.11.4. Safety and efficacy
12.11.5. Product Profile
12.12. TRAVATAN Z (travoprost ophthalmic solution) 0.004%: Alcon Research, a Novartis company
12.12.1. Product Description
12.12.2. Regulatory Milestones
12.12.3. Clinical Development
12.12.4. Safety and efficacy
12.12.5. Product Profile
12.13. LUMIGAN 0.01% (bimatoprost ophthalmic solution): Allergan
12.13.1. Product Description
12.13.2. Regulatory Milestones
12.13.3. Clinical Development
12.13.4. Product Profile

13. Emerging Therapies
13.1. Key Cross Competition
13.2. Bimatoprost SR (Sustained-Release): Allergan
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.2.5. Product Profile
13.3. PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Safety and Efficacy
13.3.5. Product Profile
13.4. PRO-122: Laboratorios Sophia S.A de C.V.
13.4.1. Product Description
13.4.2. Clinical Development
13.4.3. Safety and Efficacy
13.4.4. Product Profile
13.5. Brinzolamide Ophthalmic Suspension 1%: Perrigo Company
13.5.1. Product Description
13.5.2. Clinical Development
13.5.3. Product Profile
13.6. DE-130A (latanoprost): Santen Pharmaceutical
13.6.1. Product Description
13.6.2. Clinical Development
13.6.3. Product Profile
13.7. CKD-351: Chong Kun Dang Pharmaceutical
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Product Profile
13.8. Sepetaprost (DE-126/ONO-9054): Santen Inc./Ono Pharmaceutical
13.8.1. Product Description
13.8.2. Other Development Activities
13.8.3. Clinical Development
13.8.4. Product Profile
13.9. NCX 470: Nicox Ophthalmics
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.4. Product Profile
13.10. Bamosiran (SYL040012): Sylentis
13.10.1. Product Description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.4. Product Profile
13.11. ENV515 (Travoprost XR): Envisia Therapeutics
13.11.1. Product Description
13.11.2. Other Developmental Activities
13.11.3. Clinical Development
13.11.4. Product Profile
13.12. Nyxol (Phentolamine Mesylate): Ocuphire Pharma
13.12.1. Product Description
13.12.2. Other Developmental Activities
13.12.3. Clinical Development
13.12.4. Product Profile
13.13. POLAT-001: Peregrine Ophthalmic
13.13.1. Product Description
13.13.2. Other Developmental Activities
13.13.3. Clinical Development
13.13.4. Product Profile

14. Failed Therapies
14.1. Trabodenoson: Inotek Pharmaceuticals
14.1.1. Product Description
14.1.2. Other Developmental Activities
14.1.3. Clinical Development
14.1.4. Safety and Efficacy
14.1.5. Product Profile
14.2. OTX-TP (Travoprost): Ocular Therapeutix
14.2.1. Product Description
14.2.2. Other Developmental Activities
14.2.3. Clinical Development
14.2.4. Product Profile

15. Open-Angle Glaucoma (OAG): 7MM Market Analysis
15.1. Key Findings
15.2. Market Size of Open-Angle Glaucoma in 7MM
15.3. Market Size of Open-Angle Glaucoma by Therapies in the 7MM

16. United States: Market Outlook
16.1. United States Market Size
16.1.1. Total Market size of Open-Angle Glaucoma in the United States
16.1.2. Market Size of Open-Angle Glaucoma by Therapies in the US

17. EU-5 countries: Market Outlook
17.1. Germany Market Size
17.1.1. Total Market size of Open-Angle Glaucoma in Germany
17.1.2. Market Size of Open-Angle Glaucoma by therapies in Germany
17.2. France Market Size
17.2.1. Total Market size of Open-Angle Glaucoma in France
17.2.2. Market Size of Open-Angle Glaucoma by therapies in France
17.3. Italy Market Size
17.3.1. Total Market size of Open-Angle Glaucoma in Italy
17.3.2. Market Size of Open-Angle Glaucoma by therapies in Italy
17.4. Spain Market Size
17.4.1. Total Market size of Open-Angle Glaucoma in Spain
17.4.2. Market Size of Open-Angle Glaucoma by therapies in Spain
17.5. United Kingdom Market Size
17.5.1. Total Market size of Open-Angle Glaucoma in the United Kingdom
17.5.2. Market Size of Open-Angle Glaucoma by therapies in the UK

18. Japan Market Outlook
18.1. Japan Market Size
18.1.1. Total Market size of Open-Angle Glaucoma in Japan
18.1.2. Market Size of Open-Angle Glaucoma by therapies in Japan

19. Access and Reimbursement Overview of Open-Angle Glaucoma

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Appendix
23.1. Report Methodology

24. Capabilities

25. Disclaimer

26. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aerie Pharmaceuticals
  • Alcon Research, a Novartis company
  • Allergan
  • Bausch and Lomb
  • Chong Kun Dang Pharmaceutical
  • D.Western Therapeutics Institute (DWTI)/Kowa LTD.
  • Envisia Therapeutics
  • Laboratorios Sophia S.A de C.V.
  • Merck Sharp & Dohme Corp.
  • Nicox Ophthalmics
  • Novartis/Alcon Research
  • Ocuphire Pharma
  • Peregrine Ophthalmic
  • Perrigo Company
  • Santen Inc./Ono Pharmaceutical
  • Santen Pharmaceutical/Ube Industries
  • Sun Pharma Advanced Research Company Limited (SPARC)
  • Sylentis
Note: Product cover images may vary from those shown
Adroll
adroll